Ensysce Biosciences, Inc. (ENSC) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Ensysce Biosciences, Inc. is a clinical-stage biotechnology company focused on developing abuse-resistant and overdose-protected opioid therapies. The company's lead product candidate, PF614 (an extended-release TAAP prodrug of oxycodone), is in Phase 3 clinical development. The company has no approved products and has not generated revenue from product sales.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue (Federal Grants) | $960,999 | $1,319,772 |
| Net Loss | $(3,556,415) | $(1,945,573) |
| Loss Per Share (Basic & Diluted) | $(0.52) | $(1.39) |
| Cash and Cash Equivalents (End of Period) | $745,482 | $3,052,491 |
| Total Assets | $2,167,803 | $7,452,479 |
| Total Liabilities | $2,836,815 | $4,567,729 |
| Stockholders' Equity (Deficit) | $(669,012) | $2,884,750 |
| Notes Payable (Principal + Interest) | $245,849 | $306,708 |
Material Changes vs. Prior Period
- Revenue Decline: Federal grant revenue decreased by approximately $359,000 (27%) compared to Q1 2025, primarily due to the timing of research activities eligible for funding under the MPAR grant.
- Increased Operating Expenses: Total operating expenses rose by $1.24 million to $4.52 million. Research and Development (R&D) expenses increased by $1.46 million to $3.35 million, driven by increased clinical activity for the PF614 Phase 3 trial. General and Administrative (G&A) expenses decreased slightly by $225,000.
- Liquidity Deterioration: Cash and cash equivalents dropped significantly from $4.31 million at year-end 2025 to $745,482 at March 31, 2026. Net cash used in operating activities was $3.5 million.
- Equity Position: The company moved from a positive equity position of $2.88 million in Q4 2025 to a deficit of $669,012 in Q1 2026, largely due to the net loss for the quarter.
Outlook, Risks, and Subsequent Events
- Going Concern: The filing explicitly states that the company's limited revenues and significant operating losses raise substantial doubt about its ability to continue as a going concern for the next 12 months. Management estimates current cash is sufficient only through the late second quarter of 2026 without additional financing.
- Capital Needs: The company requires substantial additional funding to complete clinical trials and commercialization. It plans to raise capital through equity offerings, debt financings, or collaborations.
- Subsequent Financing (April 2026): On April 6, 2026, the company closed a private placement issuing 2,000 shares of Series B Preferred Stock for gross proceeds of $2.0 million. This transaction also included the issuance of warrants and an amendment to increase the stated value of Series B Preferred Stock.
- Debt Conversion: On April 23, 2026, a senior secured convertible promissory note held by a board member was converted into common stock and warrants.
- Risk Factors: Key risks include the potential failure of clinical trials, inability to secure additional funding, dilution from financing, and reliance on third-party CROs and CMOs.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $2.0 million raised in April 2026 to extend operations beyond the projected late Q2 2026 liquidity horizon.
- Grant Funding Status: Confirm the remaining $6.0 million in MPAR grant funding and the timeline for disbursement to ensure it covers critical R&D milestones.
- Dilution Impact: Assess the dilutive effect of the recent Series B Preferred Stock issuance and the conversion of the board member's note on existing common shareholders.
- Phase 3 Trial Progress: Review the specific status and enrollment rates of the PF614 Phase 3 clinical trial, which is the primary driver of the increased R&D spend.
- Debt Obligations: Monitor the status of the remaining 2023 Notes and any covenants associated with the new Series B Preferred Stock.